Amgen Stock

Amgen EBIT

The EBIT of Amgen (AMGN) as of Aug 9, 2026 is 11.73 B USD. In the previous year, EBIT was 7.26 B USD — a change of 61.63% (higher).

EBIT

11.73 BUSD

YoY

61.63%

Last updated:

In 2026, Amgen's EBIT was 11.73 B USD, a 61.63% increase from the 7.26 B USD EBIT recorded in the previous year.

The Amgen EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B USD)
Date
EBIT (B USD)
Jan 1, 2023
7.90 base
Jan 1, 2024
7.26 base
Jan 1, 2025
11.73 base
Jan 1, 2026 (e)
11.85 base
Jan 1, 2027 (e)
12.16 base
Jan 1, 2028 (e)
12.49 base
Jan 1, 2029 (e)
12.91 base
Jan 1, 2030 (e)
13.41 base
YEAREBIT (B USD)
2030 est 13.41
2029 est 12.91
2028 est 12.49
2027 est 12.16
2026 est 11.85
2025 11.73
2024 7.26
2023 7.90
2022 9.57
2021 7.64
2020 9.14
2019 9.67
2018 10.94
2017 9.97
2016 9.79
2015 8.47
2014 6.19
2013 5.87
2012 5.58
2011 4.31
2010 5.55
2009 5.51
2008 5.21
2007 3.98
2006 3.84
Access this data via the Eulerpool API

Amgen Revenue

Amgen Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
28.19 B USD
7.90 B USD
6.72 B USD
Jan 1, 2024
33.42 B USD
7.26 B USD
4.09 B USD
Jan 1, 2025
36.74 B USD
11.73 B USD
7.71 B USD
Jan 1, 2026 (e)
37.76 B USD
11.85 B USD
12.11 B USD
Jan 1, 2027 (e)
38.76 B USD
12.16 B USD
12.70 B USD
Jan 1, 2028 (e)
39.81 B USD
12.49 B USD
13.24 B USD
Jan 1, 2029 (e)
41.16 B USD
12.91 B USD
14.02 B USD
Jan 1, 2030 (e)
42.74 B USD
13.41 B USD
14.91 B USD

Amgen Margins

Amgen stock margins

The Amgen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amgen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amgen.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
70.02 %
28.01 %
23.83 %
Jan 1, 2024
61.53 %
21.71 %
12.24 %
Jan 1, 2025
70.80 %
31.93 %
20.99 %
Jan 1, 2026 (e)
70.80 %
31.37 %
32.07 %
Jan 1, 2027 (e)
70.80 %
31.37 %
32.77 %
Jan 1, 2028 (e)
70.80 %
31.37 %
33.26 %
Jan 1, 2029 (e)
70.80 %
31.37 %
34.06 %
Jan 1, 2030 (e)
70.80 %
31.37 %
34.88 %

Amgen Stock analysis

What does Amgen do? Amgen Inc. is a global biotechnology company focused on the development and production of pharmaceuticals. It was founded in 1980 by William K. Bowes Jr. and George B. Rathmann in Thousand Oaks, California/USA. The founders had the vision to create new treatment options for serious diseases such as cancer, autoimmune diseases, and osteoporosis. Amgen faced difficulties in its early days due to limited financial resources and setbacks in research. However, the company succeeded in developing the first recombinant therapeutic protein drug, Erythropoietin (EPO), and bringing it to the market. Today, Amgen has become one of the largest biotechnology companies in the world with over 24,000 employees worldwide. The company is known for its research and development work in oncology, kidney diseases, blood disorders, inflammation, and bone diseases. Amgen's business model involves investing in research and development to develop new drugs and commercialize them in global markets. The company follows a "biological platform" strategy, focusing on biotechnology products based on proteins and antibodies. Amgen has several product lines, including Biologics, Biosimilars, and Small Molecules. Biologics are protein-based drugs manufactured using living cells. Biosimilars are products that have similar structures to existing biologics. Small Molecules are chemically manufactured drugs. Some of Amgen's most well-known products include Epogen and Aranesp (both Erythropoietin-releasing hormones), Neulasta and Neupogen (both granulocyte colony-stimulating factors), Enbrel (a TNF inhibitor for the treatment of rheumatoid arthritis), Prolia and Xgeva (both Denosumab inhibitors for the treatment of osteoporosis), and Blincyto (a bispecific antibody against cancer). Amgen is also involved in cancer immunotherapy and has a range of medications in its portfolio, including a CAR-T immunotherapy used for certain forms of acute lymphoblastic leukemia (ALL). In addition, Amgen specializes in the development of biosimilars. In 2017, the company introduced six biosimilars to the market, including copies of Enbrel and Humira for the treatment of rheumatoid arthritis. Biosimilars have the potential to reduce the costs of patient treatment as they are typically cheaper than the original products. Furthermore, Amgen works closely with other companies and research institutions to develop innovative products and technologies. The company has numerous partnerships and licensing agreements with other companies in the biotech industry to accelerate its growth and expand its product pipeline. Overall, Amgen has successfully established itself as one of the leading biotechnology companies in the world. It is known for its innovative products, investments in research and development, and partnerships with other companies. With its wide product portfolio and commitment to producing high-quality biological products, Amgen will continue to play an important role in the healthcare industry. Amgen is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Amgen's EBIT

Amgen's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Amgen's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Amgen's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Amgen’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Amgen stock

EBIT of Amgen is 11.73 B USD in 2026.

EBIT of Amgen changed from 7.26 B USD to 11.73 B USD, representing a 61.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Amgen since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Amgen historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Amgen

All Key Metrics — Amgen